Symbiotec Pharmalab IPO Details: Date, Price Band, Review & How to Apply

Quick Answer

Symbiotec Pharmalab IPO is a book-built public issue of ₹1,757 crore. The issue includes a fresh issue of 15.21 lakh shares, aggregating to ₹150 crore, and an offer for sale of 1.63 crore shares, aggregating to ₹1,607 crore.

The IPO opened for subscription on 24 August 2026 and will close on 27 August 2026. The allotment is expected to be finalised on 28 August 2026, and the tentative listing date is 1 September 2026 on NSE and BSE.

The Symbiotec Pharmalab IPO price band is ₹938 to ₹988 per share. The lot size is 15 shares, and the minimum retail investment is ₹14,820 at the upper price band.

The issue also includes a reservation of up to 33,408 shares for employees, offered at a discount of ₹90 per share to the issue price.

Symbiotec Pharmalab IPO Overview

Symbiotec Pharmalab IPO is a mainboard public issue opening in August 2026. Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients, nutritional ingredients and specialty products.

The IPO is a book-built issue of ₹1,757 crore. It includes a fresh issue of ₹150 crore and an offer for sale of ₹1,607 crore.

This means the IPO has a large OFS component. The fresh issue proceeds go to the company, while the offer for sale proceeds go to selling shareholders.

The IPO opened on 24 August 2026 and closes on 27 August 2026. The shares are proposed to list on BSE and NSE with a tentative listing date of 1 September 2026.

For retail investors, the minimum application size is 1 lot of 15 shares, requiring ₹14,820 at the upper price band of ₹988 per share.

Investors comparing IPOs with Pre-IPO opportunities can also read Ultra’s guide on Pre-IPO vs IPO.

The company’s shareholding is expected to increase from 6,16,81,496 shares pre-issue to 6,32,02,757 shares post-issue, based on the provided data.

Symbiotec Pharmalab IPO Date and Timeline

The Symbiotec Pharmalab IPO date for subscription is 24 August 2026. The IPO closes on 27 August 2026.

Symbiotec Pharmalab IPO Price Band and Lot Size

The Symbiotec Pharmalab IPO price band is ₹938 to ₹988 per share. The face value is ₹2 per share.

Investors can apply for a minimum of 15 shares and in multiples of 15 shares thereafter.

For investors searching for Symbiotec Pharmalab IPO details price or Symbiotec Pharmalab share price, the IPO price band is ₹938 to ₹988 per share. The post-listing share price will depend on market demand, company fundamentals, subscription levels, valuation and listing-day trading.

About Symbiotec Pharmalab

Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of:

• active pharmaceutical ingredients

• nutritional ingredients

• specialty products

The company serves domestic and international markets across regulated and emerging regions.

With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform.

The company has approvals from major global regulatory bodies, including:

• United States Food and Drug Administration, or US FDA

• European Union Good Manufacturing Practices, or EU-GMP

• Ministry of Food and Drug Safety, Korea

• other global regulatory organisations

As of 30 June 2025, the company operated two industrial-scale API manufacturing facilities with:

• maximum chemical synthesis capacity of 584.67 metric tonnes

• fermentation capacity of 300 kilolitres

Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance and sustainable production processes. It supports pharmaceutical, nutraceutical and wellness industries by providing ingredients aligned with global standards.

Key Strengths of Symbiotec Pharmalab

The company’s strengths include:

• Global leadership in corticosteroid and steroidal hormone APIs

• Long-standing relationships with domestic and international customers

• Vertically integrated manufacturing platform

• Strong regulatory track record

• Sustainable manufacturing practices

• Continuous investment in research and development

• Technological capabilities among Indian industry peers

• Ability to expand into intellectual property-driven offerings

These strengths may support the company’s long-term prospects, but investors should evaluate them along with valuation, OFS size, regulatory risk, customer concentration and pharmaceutical industry risks.

Symbiotec Pharmalab Financials

Symbiotec Pharmalab reported growth in revenue and profit between FY2025 and FY2026. According to the provided data, revenue increased by 15%, while profit after tax rose by 14% during the same period.

The company’s total income increased from ₹755.98 crore in FY2025 to ₹872.26 crore in FY2026. Profit after tax increased from ₹96.79 crore to ₹109.90 crore during the same period.

Total borrowing reduced from ₹540.92 crore in FY2025 to ₹387.91 crore in FY2026, based on the provided financials.

Symbiotec Pharmalab IPO Review

A practical Symbiotec Pharmalab IPO review should evaluate both strengths and risks.

Positive Factors

Symbiotec Pharmalab operates in the API and biotechnology manufacturing space, with a focus on steroidal hormone APIs, corticosteroid APIs, nutritional ingredients and specialty products.

The company has a long operating history and has evolved into a backward-integrated manufacturing platform. It also has regulatory approvals from global agencies such as US FDA and EU-GMP, which may be important for serving regulated markets.

Financially, the company has shown steady growth. Total income increased from ₹723.33 crore in FY2024 to ₹872.26 crore in FY2026. PAT stood at ₹109.90 crore in FY2026.

The company’s net worth also improved from ₹720.68 crore in FY2024 to ₹1,158.64 crore in FY2026.

Points to Watch

The IPO has a large offer for sale component of ₹1,607 crore, while the fresh issue is ₹150 crore. Since OFS proceeds go to selling shareholders, investors should understand the use of proceeds carefully.

The company operates in a regulated pharmaceutical manufacturing business. Regulatory inspections, quality compliance, product approvals and export market requirements can affect operations.

Borrowing remains significant at ₹387.91 crore in FY2026, even though it reduced from FY2025 levels.

Investors should also evaluate valuation, margins, customer concentration, product concentration and industry competition before applying.

Why Investors May Consider Symbiotec Pharmalab IPO

This section is not a recommendation to apply. It only highlights factors investors may evaluate.

1. Established API Manufacturing Business

Symbiotec Pharmalab has a long operating history and specialises in APIs, nutritional ingredients and specialty products.

2. Global Regulatory Approvals

Approvals from US FDA, EU-GMP, Korean authorities and other global regulatory organisations may support the company’s ability to serve regulated markets.

3. Backward-Integrated Manufacturing Platform

The company has evolved into a vertically integrated manufacturing platform, which may support quality control, production efficiency and supply chain management.

4. Focus on Steroidal Hormone and Corticosteroid APIs

The company has leadership in corticosteroid and steroidal hormone APIs, according to the provided details.

5. Growth in Financials

Total income increased from ₹755.98 crore in FY2025 to ₹872.26 crore in FY2026, while PAT increased from ₹96.79 crore to ₹109.90 crore.

6. Reduced Borrowing in FY2026

Total borrowing reduced from ₹540.92 crore in FY2025 to ₹387.91 crore in FY2026.

How to Apply for Symbiotec Pharmalab IPO

Investors can apply for Symbiotec Pharmalab IPO through supported broker platforms using UPI or ASBA.

The general process is:

• Log in to your broker or bank-supported IPO platform.

• Select Symbiotec Pharmalab IPO from the IPO list.

• Choose the investor category and number of lots.

• Enter the bid price within the price band of ₹938 to ₹988.

• Submit the IPO application.

• Approve the UPI mandate, if applying through UPI.

• Wait for allotment finalisation.

• If allotted, shares will be credited to the demat account before listing.

Track the listing on NSE and BSE on the tentative listing date.

Retail investors can apply for a minimum of 1 lot, which equals 15 shares and requires ₹14,820 at the upper price band.

Key Risks

1. OFS-Heavy Issue

The IPO includes an offer for sale of ₹1,607 crore, compared with a fresh issue of ₹150 crore. OFS proceeds go to selling shareholders and not to the company.

2. Regulatory Risk

Pharmaceutical and API manufacturing companies are subject to inspections, approvals and quality compliance requirements. Any adverse regulatory observation may affect operations.

3. Product Concentration Risk

The company has a focus on corticosteroid and steroidal hormone APIs. Investors should evaluate whether revenue depends heavily on specific products or therapeutic segments.

4. Export and Global Market Risk

The company serves domestic and international markets. Export sales may be affected by regulatory requirements, currency movement, trade rules and geopolitical conditions.

5. Borrowing Risk

Total borrowing stood at ₹387.91 crore in FY2026. Investors should evaluate finance costs, repayment ability and cash flows.

6. Competition Risk

API and specialty manufacturing businesses face competition from Indian and global manufacturers.

7. Valuation Risk

Investors should compare the IPO valuation with growth, margins, return ratios, peer companies and industry outlook before applying.

Final Thoughts

Symbiotec Pharmalab IPO is a ₹1,757 crore book-built issue opening on 24 August 2026 and closing on 27 August 2026. The IPO price band is ₹938 to ₹988 per share, and the lot size is 15 shares.

The company operates in the pharmaceutical and biotechnology manufacturing space, with a focus on APIs, nutritional ingredients and specialty products. It has a long operating history, global regulatory approvals, a backward-integrated manufacturing platform and leadership in corticosteroid and steroidal hormone APIs.

Financially, Symbiotec Pharmalab reported growth in total income, EBITDA and PAT between FY2025 and FY2026. PAT increased from ₹96.79 crore to ₹109.90 crore during the period.

However, investors should also consider the OFS-heavy issue structure, regulatory risk, product concentration, export exposure, borrowing levels, valuation and competition.

Investors searching for Symbiotec Pharmalab IPO details today, Symbiotec Pharmalab IPO details price, Symbiotec Pharmalab IPO date or Symbiotec Pharmalab IPO details NSE should read the RHP carefully and evaluate whether the IPO fits their risk profile.

Disclaimer: This article is for educational and informational purposes only. It is not investment advice, IPO recommendation or a suggestion to apply. IPO investments are subject to market risk, business risk, valuation risk and listing risk. Investors should read the RHP carefully and consult a qualified financial advisor before making any investment decision.

FAQs

1. What is Symbiotec Pharmalab IPO?

Symbiotec Pharmalab IPO is a book-built public issue of ₹1,757 crore. It includes a fresh issue of ₹150 crore and an offer for sale of ₹1,607 crore.

2. What is Symbiotec Pharmalab IPO date?

Symbiotec Pharmalab IPO opened on 24 August 2026 and will close on 27 August 2026.

3. What is the Symbiotec Pharmalab IPO price band?

The Symbiotec Pharmalab IPO price band is ₹938 to ₹988 per share.

4. What is the lot size for Symbiotec Pharmalab IPO?

The lot size for Symbiotec Pharmalab IPO is 15 shares.

5. What is the minimum investment for retail investors?

The minimum retail investment is ₹14,820 for 1 lot of 15 shares at the upper price band of ₹988 per share.

6. When is Symbiotec Pharmalab IPO allotment expected?

The allotment for Symbiotec Pharmalab IPO is expected to be finalised on 28 August 2026.

7. When will Symbiotec Pharmalab IPO list?

Symbiotec Pharmalab IPO is tentatively scheduled to list on NSE and BSE on 1 September 2026.

8. Who is the registrar of Symbiotec Pharmalab IPO?

MUFG Intime India Pvt. Ltd. is the registrar of Symbiotec Pharmalab IPO.

9. Who is the book running lead manager for Symbiotec Pharmalab IPO?

JM Financial Ltd. is the book running lead manager for the issue.

10. What is Symbiotec Pharmalab share price?

The IPO price band is ₹938 to ₹988 per share. The post-listing share price will depend on market demand, subscription levels, company fundamentals and listing-day trading.

11. Is Symbiotec Pharmalab profitable?

Yes. Based on the provided financials, Symbiotec Pharmalab reported PAT of ₹109.90 crore in FY2026, ₹96.79 crore in FY2025 and ₹100.06 crore in FY2024.

12. What is Symbiotec Pharmalab Ltd DRHP or RHP?

The DRHP or RHP contains detailed information about the company, IPO structure, financials, risk factors, promoters, business model and use of proceeds. Investors should read the RHP carefully before applying.

13. Should investors apply for Symbiotec Pharmalab IPO?

Investors should evaluate the RHP, financials, valuation, OFS component, regulatory risks, business risks and personal suitability before deciding. This article does not provide investment advice or an IPO recommendation.